Recent Updates
Recently added Catalysts
LFCR Positive Sentiment Score: 75/100

Lifecore Biomedical to Participate in Upcoming Investor and Industry Conferences

Key Takeaway: Lifecore Biomedical, Inc. (NASDAQ: LFCR) announced its participation in several upcoming investor and industry conferences, showcasing its commitment to engaging with the investment community. CEO Paul Josephs will deliver a corporate presentation and participate in various investor meetings at the TD Cowen Health Care Conference in Boston, while also joining a fireside chat at the KeyBanc Capital Markets Healthcare Forum in New York. These events aim to strengthen relationships with current and prospective customers, emphasizing Lifecore's experience in contract development and manufacturing for sterile injectable products.

Market Sentiment Analysis

POSITIVE FACTORS

  • Lifecore Biomedical is engaging with investors, indicating confidence and transparency.
  • Participation in multiple prestigious conferences suggests strong industry presence.
  • The company highlights its expertise in sterile injectable pharmaceutical products.

Full Press Release Details

CHASKA, Minn., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today announced that the company will participate in multiple upcoming investor conferences and industry events. Details regarding Lifecore’s participation are as follows:
TD Cowen 45th Annual Health Care Conference
Details: Paul Josephs, chief executive officer, will deliver a corporate presentation and Lifecore management will participate in investor meetings
Presentation Date/Time: Tuesday, March 4, 2025, 9:50 – 10:20 a.m. ET
Conference Dates: March 3-5, 2025
Location: Boston, MA
KeyBanc Capital Markets Healthcare Forum
Details: Mr. Josephs will participate in a fireside chat and Lifecore management will participate in investor meetings
Fireside Chat Date/Time: Wednesday, March 19, 2025, 3:00 – 3:35 p.m. ET
Conference Dates: March 18-19, 2025
Details: Lifecore team will participate in meetings with current and prospective customers and attend networking events
Conference Dates: March 17-20, 2025
Location: New York, NY
A live webcast of the TD Cowen presentation may be accessed via a link on Lifecore’s investor website on the Investor Events & Presentations page at: https://ir.lifecore.com/events-presentations. Additionally, a replay of the webcast will be available on the Lifecore website following the conference.
About Lifecore Biomedical
Lifecore Biomedical, Inc. (Nasdaq: LFCR) is a fully integrated contract development and manufacturing organization (CDMO) that offers highly differentiated capabilities in the development, fill and finish of sterile injectable pharmaceutical products in syringes, vials, and cartridges, including complex formulations. As a leading manufacturer of premium, injectable-grade hyaluronic acid, Lifecore brings more than 40 years of expertise as a partner for global and emerging biopharmaceutical and biotechnology companies across multiple therapeutic categories to bring their innovations to market. For more information about the company, visit Lifecore’s website at www.lifecore.com.

Tags

contract manufacturing

Frequently Asked Questions

What major investor conferences will Lifecore participate in?

Lifecore will attend the TD Cowen Annual Health Care Conference and KeyBanc Capital Markets Healthcare Forum.

Who will represent Lifecore at the conferences?

CEO Paul Josephs will represent Lifecore, delivering presentations and participating in investor meetings.

Where can I access the live webcast of Lifecore's presentation?

The live webcast can be accessed on Lifecore’s investor website under Events & Presentations.

What is Lifecore's specialty in the biopharma industry?

Lifecore specializes in the development and manufacturing of sterile injectable pharmaceutical products.

How long has Lifecore been in the biopharma industry?

Lifecore has over 40 years of experience in the biopharmaceutical manufacturing sector.

Last updated: Feb 26, 2025